ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / INAB / insiders
INTS (39) PASG (34) ATYR (46) BCDA (37) ⌘ Pro Terminal →

IN8bio Inc. (INAB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.91 +0.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.91

IN8bio Inc. (INAB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $8.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INAB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, IN8bio Inc. (NASDAQ: INAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.91 (+0.97% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, INAB ranks #651 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INAB compare to INTS and PASG in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INAB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M) and PASG (Passage Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M). Among the 5-stock peer group, INAB leads on earnings multiple (N/A) while INAB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INAB?
▼

Per INAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001740279), IN8bio Inc. generated $54.4M in revenue (-36.1% YoY), -$19.4M in net income, and -$12.7M in free cash flow against $32.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.91 (-0.02%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE INAB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INAB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY INAB SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$1.18-3.4% Next Q
Q2 (-2Q)
39
Grade E$1.14-15.8% Next Q
Q3 (-1Q)
37
Grade E$0.96-5.2% Next Q
Current
34
Grade E$0.91-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INAB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INAB currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.14) and Max Pain ($0.96) forces dealer call-delta covering toward $2.87.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

INAB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INAB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INAB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INAB)

  • ✓Walkthrough of INAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.48%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.98H $0.98L $0.90C $0.91VOL 47.9K
RES: $1.58SUP: $0.86SMA50: $1.14SMA200: $1.44
$2.01$1.70$1.39$1.08$0.77RES $1.58SUP $0.86$0.912026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INAB Butterfly Map → + Track INAB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -36.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INAB)

Health Care Rank #651 of 1015 ⚔️ INTS vs INAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INAB vs. INTS, PASG, ATYR, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, IN8bio Inc. (INAB) ranks #651 by composite RQD confidence (34/100, grade E) and #902 by equity capitalization ($8.9M). Within this direct 5-issuer industry benchmark cohort, INAB leads on earnings valuation at N/A trailing P/E, while INAB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATYR currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with INAB at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INAB ACTIVE
IN8bio Inc.
E 34/100 — — -35.0% +0.97% $8.9M Benchmark Subject
INTS
Intensity Therapeutics Inc.
D- 39/100 — — -35.0% +0.88% $11.1M /ints-vs-inab →
PASG
Passage Bio Inc.
E 34/100 — — -35.0% -3.77% $11.1M /pasg-vs-inab →
ATYR
aTyr Pharma Inc.
D 46/100 — — -35.0% +27.33% $12.4M /atyr-vs-inab →
BCDA
BioCardia Inc.
D- 37/100 — — -35.0% +4.75% $13.0M /bcda-vs-inab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001740279 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IN8bio Inc. (INAB) reported GAAP revenue of $54.4M (-36.1% vs. FY2024 revenue of $85.2M , and -35.2% cumulative change since FY2023) , GAAP net income of -$19.4M, operating cash flow of -$12.7M, and free cash flow of -$12.7M (+47.4% YoY). On the balance sheet, INAB closed FY2025 with $32.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $54.4M -$19.4M -$12.7M -$12.7M $32.3M —
FY2024 (FY) 2024-12-31 $85.2M -$30.4M -$24.1M -$24.1M $20.9M —
FY2023 (FY) 2023-12-31 $84.0M -$30.0M -$23.3M -$23.3M — —

3. INAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, IN8bio Inc. (NASDAQ: INAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.91 (+0.97% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, INAB ranks #651 in composite RQD confidence.

How does INAB compare to INTS and PASG in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INAB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M) and PASG (Passage Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M). Among the 5-stock peer group, INAB leads on earnings multiple (N/A) while INAB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INAB?

Per INAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001740279), IN8bio Inc. generated $54.4M in revenue (-36.1% YoY), -$19.4M in net income, and -$12.7M in free cash flow against $32.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INAB trading relative to its 50-day, 200-day, and 52-week technical levels?

INAB last traded at $0.91 (+0.97% on volume of 9,334 shares), positioning the stock -20.18% below its 50-day simple moving average ($1.14) and -36.81% below its 200-day simple moving average ($1.44). Across its 52-week range of $0.87 to $2.73, INAB sits at the 2.2% percentile with a 14-day RSI of 36.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.02).

Direct Sub-Reports: INAB RQD Cockpit INAB 12M Forecast INAB Earnings & Move INAB Dividends & DRIP INAB Insiders & 13F INAB Whale Options INAB Profit Sankey INAB News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

INAB — IN8bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

IN8bio Inc. (INAB) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.91 (+0.97% 1D, market capitalization $8.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

IN8bio Inc. Is listed on NASDAQ and classified under the Health Care sector, in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company reported — in revenue across the FY 2023, FY 2024, and FY 2025 periods, indicating no reported revenue in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), IN8bio Inc. (INAB) reported $54.4M in annual revenue (up from $85.2M in FY2024, -36.1% YoY) and -$19.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($84.0M revenue, -$30.0M net income) through FY2025, INAB scaled operating cash flow to -$12.7M and free cash flow to -$12.7M, backed by $32.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.87 – $2.73 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain is NONE and butterfly links are empty. Upstream and downstream dependencies are — Sector correlations beyond the Health Care classification are — Investors should note that the absence of mapped links means this dataset cannot show second-order exposure to suppliers, partners, or sector peers.

  • Key Question #1: Can INAB sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $54.4M and free cash flow of -$12.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is INAB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INAB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IN8bio Inc. (INAB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INAB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INAB Bull vs. Bear Conversation Board — What's Your Call at $0.91?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INAB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INAB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.07 (+18.9%)
📌 Pinned Debate

The forensic balance sheet pillar scores 10/20 with an Altman Z of 2.5, the strongest of the five RQD pillars.

Don't sleep on INAB's setup in Health Care. The forensic balance sheet pillar scores 10/20 with an Altman Z of 2.5, the strongest of the five RQD pillars.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (34/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

Both sides have a point here — INAB's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.70 (-22.2%)
Spot @ $0.90

ROIC of -35% and a 0% FCF yield indicate the company is not currently generating cash returns on capital.

Here is the bear case nobody on the bull side wants to address on INAB: ROIC of -35% and a 0% FCF yield indicate the company is not currently generating cash returns on capital.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%